,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the 2,252,423,640 shares of voting common equity held by non affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of the registrant's most recently completed second fiscal quarter was approximately $132,442,510,032. Bristol Myers Squibb has no non voting common equity. At February 1, 2021, there were 2,240,475,153 shares of common stock outstanding.","132,442,510,032",['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,bmy,"The aggregate market value of the 2,252,423,640 shares of voting common equity held by non affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $132,442,510,032.","approximately $132,442,510,032",MONEY,"The aggregate market value of the 2,252,423,640 shares of voting common equity held by non affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $132,442,510,032.","['aggregate market value of shares', 'shares', 'non affiliates', 'reference to closing price', 'last business day of registrant', 'aggregate market value', 'common equity', 'non affiliates', 'closing price']","['', 0, '', '']",,0.0,,,"the aggregate market value of the 2,252,423,640 shares of voting common equity held by non affiliates of the registrant"
1,"The aggregate market value of the 2,252,423,640 shares of voting common equity held by non affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of the registrant's most recently completed second fiscal quarter was approximately $132,442,510,032. Bristol Myers Squibb has no non voting common equity. At February 1, 2021, there were 2,240,475,153 shares of common stock outstanding.","2,240,475,153","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,bmy,"At February 1, 2021, there were 2,240,475,153 shares of common stock outstanding.","2,240,475,153",CARDINAL,"At February 1, 2021, there were 2,240,475,153 shares of common stock outstanding.","['2,240,475,153 shares of common outstanding stock', 'common outstanding stock']","['shares of common stock outstanding', 0.8275416493415833, 'What is 2,240,475,153 ?', 'shares of common stock outstanding']",shares of common stock outstanding,0.8275416493415833,"What is 2,240,475,153 ?",shares of common stock outstanding,shares of common stock outstanding
2,"We have a share repurchase program authorized by our Board of Directors allowing for repurchases of our shares. The specific timing and number of shares repurchased will be determined by our management at its discretion and will vary based on market conditions, securities law limitations and other factors. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. The repurchases may be effected through a combination of one or more open market repurchases, privately negotiated transactions, transactions structured through investment banking institutions and other derivative transactions, relying on Rule 10b 18 and Rule 10b5 1 under the Exchange Act. The remaining share repurchase authority authorization under the program was $1.0 billion as of December 31, 2019. Our Board of Directors approved an increase of $5.0 billion to the share repurchase authorization for our common stock in February 2020, increasing the total outstanding share repurchase authorization to approximately $6.0 billion. In 2020, the ASR agreements that we executed in 2019 to repurchase an aggregate $7 billion of common stock were settled. We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020. The remaining share repurchase capacity under the share repurchase program was approximately $4.4 billion as of December 31, 2020. Refer to ""Item 8. Financial Statements and Supplementary Data—Note 16. Equity"" for additional information. In January 2021, our Board of Directors approved an increase of $2.0 billion to the share repurchase authorization for our common stock.",27,"['Stock Repurchased During Period, Shares']",us-gaap_StockRepurchasedDuringPeriodShares,sharesItemType,bmy,"We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020.",approximately 27 million,CARDINAL,"We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020.","['shares of common stock', 'common stock']","['shares of its common stock', 0.8536130785942078, 'What is approximately 27 million ?', 'shares of its common stock']",shares of its common stock,0.8536130785942078,What is approximately 27 million ?,shares of its common stock,common stock repurchases
3,"We have a share repurchase program authorized by our Board of Directors allowing for repurchases of our shares. The specific timing and number of shares repurchased will be determined by our management at its discretion and will vary based on market conditions, securities law limitations and other factors. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. The repurchases may be effected through a combination of one or more open market repurchases, privately negotiated transactions, transactions structured through investment banking institutions and other derivative transactions, relying on Rule 10b 18 and Rule 10b5 1 under the Exchange Act. The remaining share repurchase authority authorization under the program was $1.0 billion as of December 31, 2019. Our Board of Directors approved an increase of $5.0 billion to the share repurchase authorization for our common stock in February 2020, increasing the total outstanding share repurchase authorization to approximately $6.0 billion. In 2020, the ASR agreements that we executed in 2019 to repurchase an aggregate $7 billion of common stock were settled. We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020. The remaining share repurchase capacity under the share repurchase program was approximately $4.4 billion as of December 31, 2020. Refer to ""Item 8. Financial Statements and Supplementary Data—Note 16. Equity"" for additional information. In January 2021, our Board of Directors approved an increase of $2.0 billion to the share repurchase authorization for our common stock.",1.6,"['Stock Repurchased During Period, Value']",us-gaap_StockRepurchasedDuringPeriodValue,monetaryItemType,bmy,"We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020.",$1.6 billion,MONEY,"We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020.","['shares of common stock', 'common stock']","['27 million shares of its common stock', 0.48651841282844543, 'What is $1.6 billion ?', '27 million shares of its common stock']",27 million shares of its common stock,0.4865184128284454,What is $1.6 billion ?,27 million shares of its common stock,We repurchased approximately 27 million shares of its common stock.
4,"We have a share repurchase program authorized by our Board of Directors allowing for repurchases of our shares. The specific timing and number of shares repurchased will be determined by our management at its discretion and will vary based on market conditions, securities law limitations and other factors. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. The repurchases may be effected through a combination of one or more open market repurchases, privately negotiated transactions, transactions structured through investment banking institutions and other derivative transactions, relying on Rule 10b 18 and Rule 10b5 1 under the Exchange Act. The remaining share repurchase authority authorization under the program was $1.0 billion as of December 31, 2019. Our Board of Directors approved an increase of $5.0 billion to the share repurchase authorization for our common stock in February 2020, increasing the total outstanding share repurchase authorization to approximately $6.0 billion. In 2020, the ASR agreements that we executed in 2019 to repurchase an aggregate $7 billion of common stock were settled. We also repurchased approximately 27 million shares of its common stock for $1.6 billion during the year ended December 31, 2020. The remaining share repurchase capacity under the share repurchase program was approximately $4.4 billion as of December 31, 2020. Refer to ""Item 8. Financial Statements and Supplementary Data—Note 16. Equity"" for additional information. In January 2021, our Board of Directors approved an increase of $2.0 billion to the share repurchase authorization for our common stock.",4.4,"['Stock Repurchase Program, Remaining Authorized Repurchase Amount']",us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1,monetaryItemType,bmy,"The remaining share repurchase capacity under the share repurchase program was approximately $4.4 billion as of December 31, 2020.",approximately $4.4 billion,MONEY,"The remaining share repurchase capacity under the share repurchase program was approximately $4.4 billion as of December 31, 2020.","['remaining repurchase capacity under repurchase program', 'repurchase capacity', 'repurchase program']","['share repurchase capacity under the share repurchase program', 0.38517144322395325, 'What is approximately $4.4 billion ?', 'share repurchase capacity under the share repurchase program']",share repurchase capacity under the share repurchase program,0.3851714432239532,What is approximately $4.4 billion ?,share repurchase capacity under the share repurchase program,share repurchase capacity
5,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",10,"['Preferred Stock, Shares Authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",10 million,CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['', 0, '', '']",,0.0,,,Preferred stock shares
6,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",10,"['Preferred Stock, Shares Authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",10 million,CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['', 0, '', '']",,0.0,,,Authorized shares
7,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,484","['Preferred Stock, Shares Issued']",us-gaap_PreferredStockSharesIssued,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,484",CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['outstanding', 0.4839181900024414, 'What is 3,484 ?', 'outstanding']",outstanding,0.4839181900024414,"What is 3,484 ?",outstanding,Convertible preferred stock issued in 2020
8,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,484","['Preferred Stock, Shares Outstanding']",us-gaap_PreferredStockSharesOutstanding,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,484",CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['outstanding', 0.4839181900024414, 'What is 3,484 ?', 'outstanding']",outstanding,0.4839181900024414,"What is 3,484 ?",outstanding,"Preferred stock, $2 convertible series, issued in 2020"
9,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,568","['Preferred Stock, Shares Outstanding']",us-gaap_PreferredStockSharesOutstanding,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,568",CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['', 0, '', '']",,0.0,,,Preferred stock shares outstanding
10,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,568","['Preferred Stock, Shares Issued']",us-gaap_PreferredStockSharesIssued,sharesItemType,bmy,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share","3,568",CARDINAL,"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share",['liquidation value'],"['', 0, '', '']",,0.0,,,"Preferred stock, $2 convertible series, par value $1 per share"
11,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",4.5,"['Common Stock, Shares Authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,bmy,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",4.5 billion,CARDINAL,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",['par value'],"['', 0, '', '']",,0.0,,,Authorized shares
12,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",4.5,"['Common Stock, Shares Authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,bmy,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",4.5 billion,CARDINAL,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",['par value'],"['', 0, '', '']",,0.0,,,authorized shares
13,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",2.9,"['Common Stock, Shares Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,bmy,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",2.9 billion,CARDINAL,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",['par value'],"['', 0, '', '']",,0.0,,,common stock shares issued
14,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",2.9,"['Common Stock, Shares Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,bmy,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",2.9 billion,CARDINAL,"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019",['par value'],"['', 0, '', '']",,0.0,,,Common stock shares issued
15,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,679,"['Treasury Stock, Shares']",us-gaap_TreasuryStockShares,sharesItemType,bmy,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,679 million,CARDINAL,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,"['Less cost of treasury stock', 'Less cost', 'Less cost', 'treasury stock']","['treasury stock', 0.9090487957000732, 'how many treasury stock ?', '679 million']",treasury stock,0.9090487957000732,how many treasury stock ?,679 million,Common shares treasury stock
16,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,672,"['Treasury Stock, Shares']",us-gaap_TreasuryStockShares,sharesItemType,bmy,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,672 million,CARDINAL,Less cost of treasury stock — 679 million common shares in 2020 and 672 million common shares in 2019,"['Less cost of treasury stock', 'Less cost', 'Less cost', 'treasury stock']","['common shares', 0.9769562482833862, 'What is 672 million ?', 'common shares']",common shares,0.9769562482833862,What is 672 million ?,common shares,2019 common shares
17,"Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Cash payments resulting for licensing arrangements, including upfront and contingent milestones previously included in operating activities in the consolidated statements of cash flows are now presented in investing activities. The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018. Deferred income previously presented separately in the consolidated statements of cash flows is now presented in Other operating assets and liabilities. These reclassifications did not have an impact on net assets or net earnings.",143,['Prior Period Reclassification Adjustment'],us-gaap_PriorPeriodReclassificationAdjustment,monetaryItemType,bmy,The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018.,$143 million,MONEY,The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018.,"['increase to net cash', 'investing activities', 'net cash', 'operating activities', 'investing activities']","['net cash used in investing activities', 0.2879311442375183, 'What is $143 million ?', 'net cash used in investing activities']",net cash used in investing activities,0.2879311442375183,What is $143 million ?,net cash used in investing activities,"Net cash provided by operating activities

Entity:
$1.1 billion
Phrase:
Net cash used in investing activities"
18,"Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Cash payments resulting for licensing arrangements, including upfront and contingent milestones previously included in operating activities in the consolidated statements of cash flows are now presented in investing activities. The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018. Deferred income previously presented separately in the consolidated statements of cash flows is now presented in Other operating assets and liabilities. These reclassifications did not have an impact on net assets or net earnings.",1.1,['Prior Period Reclassification Adjustment'],us-gaap_PriorPeriodReclassificationAdjustment,monetaryItemType,bmy,The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018.,$1.1 billion,MONEY,The adjustment resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $143 million in 2019 and $1.1 billion in 2018.,"['increase to net cash', 'investing activities', 'net cash', 'operating activities', 'investing activities']","['', 0, '', '']",,0.0,,,Net cash used in investing activities
19,"Cash is restricted when withdrawal or general use is contractually or legally restricted including escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",427,['Restricted Cash'],us-gaap_RestrictedCash,monetaryItemType,bmy,"Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",$427 million,MONEY,"Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",['Restricted cash'],"['Restricted cash', 0.9891377091407776, 'What is $427 million ?', 'Restricted cash']",Restricted cash,0.9891377091407776,What is $427 million ?,Restricted cash,"Restricted cash at December 31, 2020"
20,"Cash is restricted when withdrawal or general use is contractually or legally restricted including escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",474,['Restricted Cash'],us-gaap_RestrictedCash,monetaryItemType,bmy,"Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",$474 million,MONEY,"Restricted cash was $427 million and $474 million at December 31, 2020 and 2019, respectively.",['Restricted cash'],"['Restricted cash', 0.9672384858131409, 'What is $474 million ?', 'Restricted cash']",Restricted cash,0.9672384858131408,What is $474 million ?,Restricted cash,"Restricted cash at December 31, 2019"
21,"Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",20,"['Useful life of property, plant and equipment']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,bmy,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",20 to 50 years,DATE,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.","['estimated useful lives of related assets', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives', 'related assets']","['estimated useful lives of related assets', 0.5942838788032532, 'when is estimated useful lives of related assets ?', '20 to 50 years']",estimated useful lives of related assets,0.5942838788032532,when is estimated useful lives of related assets ?,20 to 50 years,"Useful life of buildings

Entity: 
3 to 20 years
Phrase: 
Useful life of machinery"
22,"Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",50,"['Useful life of property, plant and equipment']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,bmy,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",20 to 50 years,DATE,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.","['estimated useful lives of related assets', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives', 'related assets']","['estimated useful lives of related assets', 0.5942838788032532, 'when is estimated useful lives of related assets ?', '20 to 50 years']",estimated useful lives of related assets,0.5942838788032532,when is estimated useful lives of related assets ?,20 to 50 years,"Useful life of buildings

Entity: 
3 to 20 years 
Phrase: 
Useful life of machinery"
23,"Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",3,"['Useful life of property, plant and equipment']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,bmy,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",3 to 20 years,DATE,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.","['estimated useful lives of related assets', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives', 'related assets']","['machinery, equipment and fixtures', 0.8437246680259705, 'What is 3 to 20 years ?', 'machinery, equipment and fixtures']","machinery, equipment and fixtures",0.8437246680259705,What is 3 to 20 years ?,"machinery, equipment and fixtures",Straight line method
24,"Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",20,"['Useful life of property, plant and equipment']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,bmy,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.",20 to 50 years,DATE,"Depreciation is computed on a straight line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.","['estimated useful lives of related assets', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives', 'related assets']","['estimated useful lives of related assets', 0.5942838788032532, 'when is estimated useful lives of related assets ?', '20 to 50 years']",estimated useful lives of related assets,0.5942838788032532,when is estimated useful lives of related assets ?,20 to 50 years,"The estimated useful life of buildings

Entity: 
3 to 20 years 
Phrase: 
The estimated useful life of machinery, equipment and fixtures"
25,"Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",990,['Advertising and product promotion costs'],us-gaap_MarketingAndAdvertisingExpense,monetaryItemType,bmy,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",$990 million,MONEY,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",[],"['', 0, '', '']",,0.0,,,Advertising and product promotion costs
26,"Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",633,['Advertising and product promotion costs'],us-gaap_MarketingAndAdvertisingExpense,monetaryItemType,bmy,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",$633 million,MONEY,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",[],"['', 0, '', '']",,0.0,,,2019 Advertising and product promotion costs
27,"Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",672,['Advertising and product promotion costs'],us-gaap_MarketingAndAdvertisingExpense,monetaryItemType,bmy,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",$672 million,MONEY,"Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $990 million in 2020, $633 million in 2019 and $672 million in 2018.",[],"['', 0, '', '']",,0.0,,,2018 product promotion costs
28,"Net product sales represent more than 95% of total revenues for the years ended December 31, 2020, 2019 and 2018. Products are sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, directly to retailers, hospitals, clinics and government agencies. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of control of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product after considering when the customer obtains legal title to the product and when BMS obtains a right of payment. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.",95,"['Concentration Risk, Percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,bmy,"Net product sales represent more than 95% of total revenues for the years ended December 31, 2020, 2019 and 2018.",more than 95%,PERCENT,"Net product sales represent more than 95% of total revenues for the years ended December 31, 2020, 2019 and 2018.","['% of total revenues', 'Net product sales', 'total revenues']","['Net product sales', 0.9657195806503296, 'What is more than 95% ?', 'Net product sales']",Net product sales,0.9657195806503296,What is more than 95% ?,Net product sales,total revenues
29,"(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",106,['Prior Period Gross to Net Adjustment Impacted by New Accounting Pronouncement'],bmy_PriorPeriodGrosstoNetAdjustmentImpactedbyNewAccountingPronouncement,monetaryItemType,bmy,"(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",$106 million,MONEY,"    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.","['adjustments for provisions', 'provisions for product sales', 'changes in estimates', 'estimates', 'changes', 'product sales', 'prior periods']","['changes in estimates', 0.515719473361969, 'what is changes in estimates ?', '$106 million']",changes in estimates,0.515719473361969,what is changes in estimates ?,$106 million,provisions for product sales
30,"(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",132,['Prior Period Gross to Net Adjustment Impacted by New Accounting Pronouncement'],bmy_PriorPeriodGrosstoNetAdjustmentImpactedbyNewAccountingPronouncement,monetaryItemType,bmy,"(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",$132 million,MONEY,"    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.","['adjustments for provisions', 'provisions for product sales', 'changes in estimates', 'estimates', 'changes', 'product sales', 'prior periods']","['', 0, '', '']",,0.0,,,provisions for product sales
31,"(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",96,['Prior Period Gross to Net Adjustment Impacted by New Accounting Pronouncement'],bmy_PriorPeriodGrosstoNetAdjustmentImpactedbyNewAccountingPronouncement,monetaryItemType,bmy,"(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.",$96 million,MONEY,"    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.","['adjustments for provisions', 'provisions for product sales', 'changes in estimates', 'estimates', 'changes', 'product sales', 'prior periods']","['', 0, '', '']",,0.0,,,provisions for product sales
32,"Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized upon the adoption of ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch up adjustments to revenue affecting contract assets or contract liabilities were not material during the year ended December 31, 2020 and 2019. Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at December 31, 2020 and 2019.",338,"['Contract with Customer, Performance Obligation Satisfied in Previous Period']",us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod,monetaryItemType,bmy,"Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales.",$338 million,MONEY,"Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales.","['royalties for licensing arrangements', 'revised estimates for GTN adjustments', 'performance satisfied obligations', 'prior periods', 'licensing arrangements', 'GTN adjustments', 'period sales']","['royalties for out licensing arrangements', 0.12697787582874298, 'What is $338 million ?', 'royalties for out licensing arrangements']",royalties for out licensing arrangements,0.1269778758287429,What is $338 million ?,royalties for out licensing arrangements,"Revenue recognized from performance obligations satisfied in prior periods

Entity:
$411 million
Phrase:
Revised estimates for GTN adjustments related to prior period sales"
33,"Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized upon the adoption of ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch up adjustments to revenue affecting contract assets or contract liabilities were not material during the year ended December 31, 2020 and 2019. Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at December 31, 2020 and 2019.",411,"['Contract with Customer, Performance Obligation Satisfied in Previous Period']",us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod,monetaryItemType,bmy,"Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales.",$411 million,MONEY,"Revenue recognized from performance obligations satisfied in prior periods was $338 million in 2020 and $411 million in 2019, consisting primarily of royalties for out licensing arrangements and revised estimates for GTN adjustments related to prior period sales.","['royalties for licensing arrangements', 'revised estimates for GTN adjustments', 'performance satisfied obligations', 'prior periods', 'licensing arrangements', 'GTN adjustments', 'period sales']","['royalties for out licensing arrangements', 0.36120036244392395, 'What is $411 million ?', 'royalties for out licensing arrangements']",royalties for out licensing arrangements,0.3612003624439239,What is $411 million ?,royalties for out licensing arrangements,Revised estimates for GTN adjustments
34,"BMS and Pfizer jointly develop and commercialize Eliquis, an anticoagulant discovered by BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis except in certain countries where Pfizer commercializes Eliquis and pays BMS a sales based fee.",50,['Minimum percentage of reimbursement for development costs from alliance partner'],bmy_MinimumPercentageOfReimbursementForDevelopmentCostsFromCollaborations,percentItemType,bmy,Pfizer funds between 50% and 60% of all development costs depending on the study.,between 50% and 60%,PERCENT,Pfizer funds between 50% and 60% of all development costs depending on the study.,"['Pfizer funds between %', '% of development costs', 'development costs']","['development costs', 0.7126898169517517, 'what is development costs ?', 'between 50% and 60%']",development costs,0.7126898169517517,what is development costs ?,between 50% and 60%,Pfizer funds all development costs
35,"BMS and Pfizer jointly develop and commercialize Eliquis, an anticoagulant discovered by BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis except in certain countries where Pfizer commercializes Eliquis and pays BMS a sales based fee.",60,['Maximum percentage of reimbursement for development costs from alliance partner'],bmy_MaximumPercentageOfReimbursementForDevelopmentCostsFromCollaborations,percentItemType,bmy,Pfizer funds between 50% and 60% of all development costs depending on the study.,between 50% and 60%,PERCENT,Pfizer funds between 50% and 60% of all development costs depending on the study.,"['Pfizer funds between %', '% of development costs', 'development costs']","['development costs', 0.7126898169517517, 'what is development costs ?', 'between 50% and 60%']",development costs,0.7126898169517517,what is development costs ?,between 50% and 60%,all development costs
36,"BMS did not allocate consideration to the rights transferred to Pfizer as such rights were not sold separately by BMS or any other party, nor could Pfizer receive any benefit for the delivered rights without the fulfillment of other ongoing obligations by BMS under the alliance agreement. As such, the global alliance was treated as a single unit of accounting and upfront proceeds and any subsequent contingent milestone proceeds are amortized over the expected period of BMS's co promotion obligation through the market exclusivity period. BMS received $884 million in non refundable upfront, milestone and other licensing payments which are amortized and included in Other (income)/expense, net as Eliquis was not a commercial product at the commencement of the alliance.",884,"['Total upfront, milestone and other licensing payments received to date']",bmy_TotalUpfrontLicensingAndMilestoneReceipts,monetaryItemType,bmy,"BMS received $884 million in non refundable upfront, milestone and other licensing payments which are amortized and included in Other (income)/expense, net as Eliquis was not a commercial product at the commencement of the alliance.",$884 million,MONEY,"BMS received $884 million in non refundable upfront, milestone and other licensing payments which are amortized and included in Other expense, net as Eliquis was not a commercial product at the commencement of the alliance.","['net as Eliquis', 'commercial product at commencement', 'commencement of alliance', 'refundable upfront', 'Other expense']","['non refundable upfront, milestone and other licensing payments', 0.8057230710983276, 'What is $884 million ?', 'non refundable upfront, milestone and other licensing payments']","non refundable upfront, milestone and other licensing payments",0.8057230710983276,What is $884 million ?,"non refundable upfront, milestone and other licensing payments",Non refundable milestone payments
37,"BMS and Ono jointly develop and commercialize Opdivo, Yervoy and several BMS investigational compounds in Japan, South Korea and Taiwan. BMS is responsible for supply of the products. Profits, losses and development costs are shared equally for all combination therapies involving compounds of both parties. Otherwise, sharing is 80% and 20% for activities involving only one of the party's compounds.",80,['Profit sharing involving only one compound   maximum'],bmy_Profitsharinginvolvingonlyonecompoundmaximum,percentItemType,bmy,"Otherwise, sharing is 80% and 20% for activities involving only one of the party’s compounds.",80% and 20%,PERCENT,"Otherwise, sharing is 80% and 20% for activities involving only one of the party’s compounds.",[],"['sharing', 0.9965549111366272, 'What is 80% and 20% ?', 'sharing']",sharing,0.9965549111366272,What is 80% and 20% ?,sharing,Sharing for activities involving only one party's compounds
38,"BMS and Ono jointly develop and commercialize Opdivo, Yervoy and several BMS investigational compounds in Japan, South Korea and Taiwan. BMS is responsible for supply of the products. Profits, losses and development costs are shared equally for all combination therapies involving compounds of both parties. Otherwise, sharing is 80% and 20% for activities involving only one of the party's compounds.",20,['Profit sharing involving only one compound   minimum'],bmy_Profitsharinginvolvingonlyonecompoundminimum,percentItemType,bmy,"Otherwise, sharing is 80% and 20% for activities involving only one of the party’s compounds.",80% and 20%,PERCENT,"Otherwise, sharing is 80% and 20% for activities involving only one of the party’s compounds.",[],"['sharing', 0.9965549111366272, 'What is 80% and 20% ?', 'sharing']",sharing,0.9965549111366272,What is 80% and 20% ?,sharing,Sharing is for activities involving only one of the party's compounds
39,BMS and Ono also jointly develop and commercialize Orencia in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. A co promotion fee of 60% is paid when a sale is made to the other party's assigned customer.,60,['Co promotion fee percentage'],bmy_Copromotionfeepercentage,percentItemType,bmy,A co promotion fee of 60% is paid when a sale is made to the other party’s assigned customer.,60%,PERCENT,A co promotion fee of 60% is paid when a sale is made to the other party’s assigned customer.,"['co promotion fee of %', 'co promotion fee']","['co promotion fee', 0.9785125851631165, 'what is co promotion fee ?', '60%']",co promotion fee,0.9785125851631165,what is co promotion fee ?,60%,co promotion fee
40,"BMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.",4,['Royalty rate due to regulatory approvals'],bmy_RoyaltyRateFromSalesUponRegulatoryApprovals,percentItemType,bmy,"Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.",4%,PERCENT,"Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.","['royalties of %', '% in North America', '% in territories', 'subject countries', 'customary adjustments']","['% in North America', 0.9040892720222473, 'what is % in North America ?', '4%']",% in North America,0.9040892720222472,what is % in North America ?,4%,"North America royalties

Entity: 
15%
Phrase: 
All territories royalties"
41,"BMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.",15,['Royalty rate due to regulatory approvals'],bmy_RoyaltyRateFromSalesUponRegulatoryApprovals,percentItemType,bmy,"Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.",15%,PERCENT,"Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.","['royalties of %', '% in North America', '% in territories', 'subject countries', 'customary adjustments']","['% in territories', 0.9557438492774963, 'what is % in territories ?', '15%']",% in territories,0.9557438492774964,what is % in territories ?,15%,All territories excluding the three countries listed above
42,"In 2018, BMS and Nektar commenced a worldwide license and collaboration for the development and commercialization of Bempegaldesleukin (NKTR 214), Nektar's investigational immuno stimulatory therapy designed to selectively expand specific cancer fighting T cells and natural killer cells directly in the tumor micro environment. In January 2020, the parties amended the collaboration agreement. The Opdivo and NKTR 214 combination therapy is currently in Phase III clinical studies for metastatic melanoma, adjuvant melanoma, muscle invasive bladder cancer and RCC. A joint development plan agreed by the parties as part of the original agreement, and updated as part of the January 2020 amendment, specifies development in certain indications and tumor types with each party responsible for the supply of their own product. BMS's share of the development costs associated with therapies comprising a BMS medicine used in combination with NKTR 214 is 67.5%, subject to certain cost caps for Nektar. The January 2020 amendment retains the cost sharing percentages from the original agreement. The parties will also jointly commercialize the therapies, subject to regulatory approval. BMS's share of global NKTR 214 profits and losses will be 35% subject to certain annual loss caps for Nektar.",67.5,"['Cost Share, Percentage, Combination Studies']",bmy_CostSharePercentageCombinationStudies,percentItemType,bmy,"BMS’s share of the development costs associated with therapies comprising a BMS medicine used in combination with NKTR 214 is 67.5%, subject to certain cost caps for Nektar.",67.5%,PERCENT,"BMS’s share of the development costs associated with therapies comprising a BMS medicine used in combination with NKTR 214 is 67.5%, subject to certain cost caps for Nektar.","['share of development costs', 'combination with NKTR', 'certain cost caps for Nektar', 'development costs', 'BMS medicine', 'certain cost caps']","['development costs', 0.8381480574607849, 'what is development costs ?', '67.5%']",development costs,0.8381480574607849,what is development costs ?,67.5%,BMS's share of development costs
43,"In 2018, BMS and Nektar commenced a worldwide license and collaboration for the development and commercialization of Bempegaldesleukin (NKTR 214), Nektar's investigational immuno stimulatory therapy designed to selectively expand specific cancer fighting T cells and natural killer cells directly in the tumor micro environment. In January 2020, the parties amended the collaboration agreement. The Opdivo and NKTR 214 combination therapy is currently in Phase III clinical studies for metastatic melanoma, adjuvant melanoma, muscle invasive bladder cancer and RCC. A joint development plan agreed by the parties as part of the original agreement, and updated as part of the January 2020 amendment, specifies development in certain indications and tumor types with each party responsible for the supply of their own product. BMS's share of the development costs associated with therapies comprising a BMS medicine used in combination with NKTR 214 is 67.5%, subject to certain cost caps for Nektar. The January 2020 amendment retains the cost sharing percentages from the original agreement. The parties will also jointly commercialize the therapies, subject to regulatory approval. BMS's share of global NKTR 214 profits and losses will be 35% subject to certain annual loss caps for Nektar.",35,['Percentage of Pretax Profit and Loss Shared with BMS'],bmy_PercentageofPretaxProfitandLossSharedwithBMS,percentItemType,bmy,BMS’s share of global NKTR 214 profits and losses will be 35% subject to certain annual loss caps for Nektar.,35%,PERCENT,BMS’s share of global NKTR 214 profits and losses will be 35% subject to certain annual loss caps for Nektar.,"['share of global profits', 'subject to certain annual loss caps', 'certain annual loss caps for Nektar', 'global profits', 'certain annual loss caps']","['certain annual loss caps for Nektar', 0.9455452561378479, 'what is certain annual loss caps for Nektar ?', '35%']",certain annual loss caps for Nektar,0.945545256137848,what is certain annual loss caps for Nektar ?,35%,NKTR 214 profits and losses
44,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",1.85,['Upfront payments for licensing and alliance arrangements'],bmy_UpfrontPaymentsMadeToCollaborativePartner,monetaryItemType,bmy,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,$1.85 billion,MONEY,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,"['shares of common stock', 'common stock', '% ownership interest']","['', 0, '', '']",,0.0,,,Nektar common stock
45,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",8.3,['Equity Received in Collaborative Partner'],bmy_EquityReceivedinCollaborativePartner,sharesItemType,bmy,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,8.3 million,CARDINAL,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,"['shares of common stock', 'common stock', '% ownership interest']","['shares of common stock', 0.9157316088676453, 'how many shares of common stock ?', '8.3 million']",shares of common stock,0.9157316088676452,how many shares of common stock ?,8.3 million,Nektar common stock
46,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",4.8,['Ownership Interest'],bmy_OwnershipInterest,percentItemType,bmy,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,4.8%,PERCENT,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,"['shares of common stock', 'common stock', '% ownership interest']","['common stock', 0.49268433451652527, 'what is common stock ?', 'a 4.8% ownership interest']",common stock,0.4926843345165252,what is common stock ?,a 4.8% ownership interest,Nektar common stock ownership interest
47,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",800,['Equity Investment in Collaborative Partner'],bmy_EquityInvestmentinCollaborativePartner,monetaryItemType,bmy,The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar’s stock price on the date of closing and current limitations on trading the securities.,$800 million,MONEY,The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar’s stock price on the date of closing and current limitations on trading the securities.,"['amount of upfront payment', 'stock price on date', 'date of closing limitations', 'closing limitations', 'upfront payment', 'equity investment', 'stock price']","['amount of upfront payment', 0.9791592955589294, 'what is amount of upfront payment ?', '$800 million']",amount of upfront payment,0.9791592955589294,what is amount of upfront payment ?,$800 million,Nektar's stock price
48,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",1.05,['Upfront payment allocated to research and development expenses'],bmy_Upfrontpaymentallocatedtoresearchanddevelopmentexpenses,monetaryItemType,bmy,The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018.,$1.05 billion,MONEY,The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018.,['upfront payment'],"['upfront payment', 0.7806835174560547, 'What is $1.05 billion ?', 'upfront payment']",upfront payment,0.7806835174560547,What is $1.05 billion ?,upfront payment,upfront payment
49,"BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest. BMS's equity ownership is subject to certain lock up, standstill and voting provisions for a five year period. The amount of the upfront payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the upfront payment was allocated to the rights discussed above and included in Research and development expense in 2018. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales based milestones over the life of the alliance period. Research and development expense payable under this agreement with Nektar was $132 million in 2020, $108 million in 2019 and $59 million in 2018.",1.8,['Consideration for contingent development and regulatory approval'],bmy_Considerationforcontingentdevelopmentandregulatoryapproval,monetaryItemType,bmy,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,$1.85 billion,MONEY,BMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.,"['shares of common stock', 'common stock', '% ownership interest']","['', 0, '', '']",,0.0,,,Nektar common stock
